Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome

Bone Marrow Transplant. 2014 Mar;49(3):465-6. doi: 10.1038/bmt.2013.209. Epub 2014 Jan 13.

Authors

K Patel¹, M Nusrat², N Shah³, Q Bashir³, S Parmar³, J Shah⁴, S Thomas⁴, D Weber⁴, R Z Orlowski⁴, R Champlin³, M H Qazilbash³

Affiliations

¹ Hematology Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² The University of Texas UT Health Internal Medicine Residency Program, Houston, TX, USA.
³ Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Publication types

Letter

MeSH terms

Adult
Antigens, CD34 / metabolism
Disease-Free Survival
Female
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation*
Humans
Male
Melphalan / therapeutic use
Middle Aged
POEMS Syndrome / immunology
POEMS Syndrome / therapy*
Time Factors
Transplantation, Autologous
Treatment Outcome

Substances

Antigens, CD34
Melphalan

Grants and funding